Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18326356 | 1.00 | CYP19A1 (0.40) | CYP19A1CYP17A1ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL24335753 | 1.00 | CYP19A1 (0.40) | CYP19A1CYP17A1ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL8241125 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MAPTHPGDPOLB | |
| SCHEMBL7688541 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MAPTHPGDPOLB | |
| SCHEMBL8115614 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MAPTHPGDPOLB | |
| SCHEMBL18326357 | 0.78 | CYP19A1 (0.45) | CYP19A1CYP17A1CYP3A4MAPTSLC6A2 | |
| SCHEMBL17789740 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTGAA | |
| SCHEMBL15687372 | 0.76 | ENPP2 (0.43) | ALDH1A1 | |
| SCHEMBL5958113 | 0.76 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL18504414 | 0.76 | ALDH1A1 (0.39) | ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214197-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060812-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | CYP19A1 4454/4885CYP17A1 4453/4885ALDH1A1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.